Cancer Advisor

Abstract Background Pancreatic cancer remains one of the most lethal malignancies despite modern chemotherapy. Increasing public interest has emerged around repurposed antiparasitic drugs such as fenbendazole, mebendazole, and ivermectin. Objective To reorganise and analyse anecdotal pancreatic cancer case reports involving fenbendazole and ivermectin-based protocols in order to identify recurring response patterns and clinically relevant subgroups. Methods Publicly available anecdotal reports were reviewed qualitatively and reorganised according to biomarker response, metastatic pattern, chemotherapy use, histology, and adjunct metabolic therapies. Results Recurring themes included rapid CA19-9 decline, apparent liver metastasis responses, heavy reliance on combination chemotherapy, delayed-response patterns, and extensive use of nutraceutical adjuncts. Most reported responders received multi-modal therapy rather than antiparasitic monotherapy. Conclusion The reports are highly vulner...

Edited and Updated: June 2026  Caution to the Reader: This is a complex, evolving topic rooted in molecular biology and evolutionary dynamics. The material below has been distilled for clinical accessibility while preserving strict mechanistic accuracy. Key conceptual frameworks from the Care Oncology Clinic (COC) protocol and Thomas Seyfried’s press–pulse model are integrated throughout. Introduction Clinicians utilizing a metabolic framework often combine 4–5 repurposed prescription agents with 4–5 nutraceuticals. While this approach frequently yields 1–2 years of sustained, stable response, acquired resistance can emerge rapidly, turning stable disease into aggressive progression. When this occurs, critical clinical questions arise: How should the regimen be modified? Should mechanistically similar agents be cycled more frequently? Should dosing be intermittent rather than continuous? What ...